"Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

"Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation". / Wareham, Neval E; Li, Qiuju; Sengeløv, Henrik; Da Cunha-Bang, Caspar; Gustafsson, Finn; Heilmann, Carsten; Perch, Michael; Rasmussen, Allan; Sørensen, Søren Schwartz; Mocroft, Amanda; Lundgren, Jens D.

I: Journal of Cancer Research and Clinical Oncology, Bind 145, Nr. 12, 12.2019, s. 3125-3135.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Wareham, NE, Li, Q, Sengeløv, H, Da Cunha-Bang, C, Gustafsson, F, Heilmann, C, Perch, M, Rasmussen, A, Sørensen, SS, Mocroft, A & Lundgren, JD 2019, '"Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"', Journal of Cancer Research and Clinical Oncology, bind 145, nr. 12, s. 3125-3135. https://doi.org/10.1007/s00432-019-03039-2

APA

Wareham, N. E., Li, Q., Sengeløv, H., Da Cunha-Bang, C., Gustafsson, F., Heilmann, C., Perch, M., Rasmussen, A., Sørensen, S. S., Mocroft, A., & Lundgren, J. D. (2019). "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation". Journal of Cancer Research and Clinical Oncology, 145(12), 3125-3135. https://doi.org/10.1007/s00432-019-03039-2

Vancouver

Wareham NE, Li Q, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C o.a. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation". Journal of Cancer Research and Clinical Oncology. 2019 dec.;145(12):3125-3135. https://doi.org/10.1007/s00432-019-03039-2

Author

Wareham, Neval E ; Li, Qiuju ; Sengeløv, Henrik ; Da Cunha-Bang, Caspar ; Gustafsson, Finn ; Heilmann, Carsten ; Perch, Michael ; Rasmussen, Allan ; Sørensen, Søren Schwartz ; Mocroft, Amanda ; Lundgren, Jens D. / "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation". I: Journal of Cancer Research and Clinical Oncology. 2019 ; Bind 145, Nr. 12. s. 3125-3135.

Bibtex

@article{c14e96f6592c4d89bfb40798737a3f70,
title = "{"}Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation{"}",
abstract = "PURPOSE: Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof.METHODS: Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression.RESULTS: During a median of 3.4 (IQR 1.3-6.4) and 2.6 (0.8-5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0-4.3) and 2.2 (1.6-3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4-25.7) and 25.4 (5.1-126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8-3.4) and 2.3 (1.4-3.9), resp.), but neither with prior cancer nor type of immunosuppressants.CONCLUSION: Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.",
keywords = "Adult, Cohort Studies, Female, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Immunosuppressive Agents/adverse effects, Incidence, Male, Middle Aged, Neoplasms/etiology, Neoplasms, Second Primary/etiology, Organ Transplantation/adverse effects, Risk Factors, Transplant Recipients, Young Adult",
author = "Wareham, {Neval E} and Qiuju Li and Henrik Sengel{\o}v and {Da Cunha-Bang}, Caspar and Finn Gustafsson and Carsten Heilmann and Michael Perch and Allan Rasmussen and S{\o}rensen, {S{\o}ren Schwartz} and Amanda Mocroft and Lundgren, {Jens D}",
year = "2019",
month = dec,
doi = "10.1007/s00432-019-03039-2",
language = "English",
volume = "145",
pages = "3125--3135",
journal = "Zeitschrift fur Krebsforschung",
issn = "0171-5216",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

AU - Wareham, Neval E

AU - Li, Qiuju

AU - Sengeløv, Henrik

AU - Da Cunha-Bang, Caspar

AU - Gustafsson, Finn

AU - Heilmann, Carsten

AU - Perch, Michael

AU - Rasmussen, Allan

AU - Sørensen, Søren Schwartz

AU - Mocroft, Amanda

AU - Lundgren, Jens D

PY - 2019/12

Y1 - 2019/12

N2 - PURPOSE: Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof.METHODS: Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression.RESULTS: During a median of 3.4 (IQR 1.3-6.4) and 2.6 (0.8-5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0-4.3) and 2.2 (1.6-3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4-25.7) and 25.4 (5.1-126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8-3.4) and 2.3 (1.4-3.9), resp.), but neither with prior cancer nor type of immunosuppressants.CONCLUSION: Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.

AB - PURPOSE: Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof.METHODS: Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression.RESULTS: During a median of 3.4 (IQR 1.3-6.4) and 2.6 (0.8-5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0-4.3) and 2.2 (1.6-3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4-25.7) and 25.4 (5.1-126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8-3.4) and 2.3 (1.4-3.9), resp.), but neither with prior cancer nor type of immunosuppressants.CONCLUSION: Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.

KW - Adult

KW - Cohort Studies

KW - Female

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Immunosuppressive Agents/adverse effects

KW - Incidence

KW - Male

KW - Middle Aged

KW - Neoplasms/etiology

KW - Neoplasms, Second Primary/etiology

KW - Organ Transplantation/adverse effects

KW - Risk Factors

KW - Transplant Recipients

KW - Young Adult

U2 - 10.1007/s00432-019-03039-2

DO - 10.1007/s00432-019-03039-2

M3 - Journal article

C2 - 31587105

VL - 145

SP - 3125

EP - 3135

JO - Zeitschrift fur Krebsforschung

JF - Zeitschrift fur Krebsforschung

SN - 0171-5216

IS - 12

ER -

ID: 236325568